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Initial Decision MiR-DCi16-0020 
We thank Treiber et al for sharing their data in relation to a greater prevalence of 
painful neuropathy and slower walking speeds in their patients taking a statin [1]. 
They suggest that some of the differences observed in our study could be explained 
by treatment with statins. We have utilised our data to assess if statins may contribute 
to lower limb weakness or muscle atrophy and neuropathy. 
We have compared our study parameters between T2DM patients on a statin (n=16) 
to those who were not on a statin (n=4; Table 1). The interpretation of our data is 
limited and cautious because of the small number of patients not on a statin and also 
the lack of matching for age, weight and BMI. Nevertheless, muscle strength of the 
lower limb (knee extensors and ankle plantar flexors) did not differ significantly. 
Muscle volumes for the knee extensors (P=0.04) and flexors (P=0.09) were lower, 
with no difference in the ankle plantar (P=0.21) and dorsiflexor (P=0.24) muscle 
volumes of T2DM patients on a statin compared to patients not on a statin.  
Diabetic patients on a statin were older and it is well known that muscle mass 
declines as a result of ageing due to a reduction in skeletal muscle fibre number, 
size and length [2]. Whilst it has been suggested that a reduction in muscle size can 
result in reduced motor neuron unit activation and decreased muscle force and 
power generation [2], this was not observed in the present study. Another possible 
explanation is that the older individuals on a statin have a reduction in physical 
activity, which particularly affects the antigravity muscles such as the knee 
extensors. Reduced muscle size, reduced muscle activation capacity and ageing are 
of course highly correlated with reduced muscle strength [3], but in the present study 
there was no difference between those patient taking a statin compared to those not 
on a statin.  
The loss of muscle mass is also associated with diabetic neuropathy, and in the 
present study vibration perception threshold (VPT) (P=0.0001) and NDS (P=0.09) 
were significantly higher indicative of neuropathy in diabetic patients on a statin 
compared to patients not on a statin, similar to the findings of Treiber et al. Of course 
whether or not a T2DM patient is on a statin will always be confounded by age, 
cardiovascular risk and the presence of other microvascular complications [4]. 
Furthermore, contrary to the studies cited by Trieber and colleagues, a recent large 
study has shown that treatment with statins may prevent the development of diabetic 
neuropathy [5]. And of course whether or not a patient is taking a statin depends on 
whether they can tolerate it, particularly in relation to vitamin D deficiency [6]. A large 
prospective study is required to establish the potential relationship between statin 
use, muscle volume and strength and indeed walking ability and falls in diabetes.  
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Table 1. Clinical demographics and measures of neuropathy, muscle strength and 
volume in T2DM patients treated with or without a statin.  
 
Data are expressed as Mean ± SD. BMI: Body mass index; VPT: Vibration perception 
threshold; NDS: Neuropathy disability score. 
 
Variables T2DM-No Statin (n=4/20) T2DM- Statin (n=16/20)  P value 
Age (years) 50±13.4 66±7.5 0.09 
Body mass (kg) 97.6±18.8 79.1±16.7 0.14 
BMI (kg/m2) 32.7±5.6 28.5±3.4 0.24 
VPT (Hz) 5.3±1.3 15.7±8.4 0.0001 
NDS (0-10) 1.2±1.8 3.5±2.5 0.09 
Muscle strength (Nm/kg)    
Knee extensors  1.4±0.4 1.3±0.5 0.47 
Ankle plantar flexors  0.8±0.3 0.6±0.2 0.28 
Muscle volume (cm3)    
Knee extensors  1370.9±316.1 873.7±356.2 0.04 
Knee flexors 705.1±199.3 473.4±204.8 0.09 
Ankle plantar flexors 882.0±323.3.7 629.9±155.2 0.21 
Ankle dorsiflexors 253.9±83.9 192.4±39.6 0.24 
